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Abstract
Background—Group B Streptococcus (GBS) and Escherichia coli (E. coli) cause serious
bacterial infections (SBIs) and are associated with morbidity and mortality in newborn infants.
Intrapartum antibiotic prophylaxis (IAP) reduces early-onset SBIs caused by GBS. The effect of
IAP on late-onset SBIs caused by these organisms is unknown.
Methods—We examined all blood, urine, and cerebrospinal fluid culture results from infants
admitted from 1997–2010 to 322 neonatal intensive care units managed by the Pediatrix Medical
Group. We identified infants with positive cultures for GBS or E. coli and compared the incidence
of early- and late-onset SBI for each organism in the time period before (1997–2001) and after
(2002–2010) universal IAP recommendations.
Results—We identified 716,407 infants with cultures, 2520 (0.4%) with cultures positive for
GBS and 2476 (0.3%) with cultures positive for E. coli. The incidence of GBS early-onset SBI
decreased between 1997–2001 and 2002–2010 from 3.5 to 2.6 per 1000 admissions, and the
incidence for E. coli early-onset SBI remained stable (1.4 per 1000 admissions in both time
periods). Over the same time period, the incidence of GBS late-onset SBI increased from 0.8 to
1.1 per 1000 admissions, and incidence of E. coli late-onset SBI increased from 2.2 to 2.5 per
1000 admissions.
Conclusions—In our cohort, the incidence of early-onset GBS SBI decreased, while the
incidence of late-onset SBI for E. coli and GBS increased.
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Serious bacterial infections (SBIs) are a significant cause of infant morbidity and mortality.
Based on disease onset, SBIs are categorized as early-onset or late-onset.1,2 Group B
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Streptococcus (GBS) and Escherichia coli (E. coli) are the 2 most common organisms
associated with early-onset SBI.3–5 Intrapartum antibiotic prophylaxis (IAP) reduces the
incidence of early-onset GBS infections; however, invasive disease still occurs and is an
important contributor to infant mortality.6,7 Since the recommendations for risk-based
screening for GBS and use of IAP in 1996 and universal screening in 2002, the incidence of
GBS early-onset SBIs has decreased from 1.7/1000 to 0.34/1000 live births.8–11 Increased
administration of IAP has led to a change in the epidemiology of early-onset SBI among
very low birth weight (VLBW, <1500 g birth weight) infants; E. coli is now the most
common cause of early-onset SBI in this population.12 Although IAP reduces GBS early-
onset SBI, there are conflicting data regarding the relationship between IAP and the
incidence of GBS late-onset SBI.4,13
Previous studies of infants with early- and late-onset SBI included only VLBW infants, the
evaluation of a single center, or excluded urine as a source of infection.4,12 We hypothesized
that the widespread use of IAP has changed the incidence of GBS and E. coli as causes of
early-and late-onset SBI. We examined neonatal SBIs, including bloodstream infections,
urinary tract infections, and meningitis, in a large, multicenter cohort of neonatal intensive
care units (NICUs) to examine the incidence of GBS and E. coli SBIs before and after the
recommendation for universal IAP.
METHODS
Study Population
This was an observational, retrospective, cohort study of all infants admitted to 322 NICUs
managed by the Pediatrix Medical Group in the United States from 1997–2010. Data from
clinical progress notes were used to populate the data set. We reviewed neonatal and
maternal demographics, as well as the results of all cultures (blood, urine, and cerebrospinal
fluid [CSF]) in the first 120 days of life. We excluded urine cultures obtained from bag
specimens.
Definitions
We defined early-onset SBI as a positive blood, urine (obtained from a catheterization or
suprapubic tap), or CSF culture within the first 3 postnatal days. Late-onset SBI was defined
as a positive culture from 4–120 postnatal days. We considered cultures that were positive
for the same organism within a 21-day period as a single episode of infection. Gestational
age was based on the best estimate of last menstrual period, obstetrical record, and clinical
exam. The clinician recorded exposure to antenatal antibiotics and antenatal steroids in the
infant’s clinical progress note upon admission to the NICU. Type of antibiotic given prior to
delivery was not recorded.
Statistical Analysis
The unit of measurement for analysis was the infant. We used standard summary statistics
including means, medians, and ranges to describe continuous variables, and frequency
counts and percentages to describe categorical variables. Cumulative incidences of GBS and
E. coli SBIs were calculated separately for early- and late-onset disease by dividing the total
number of SBIs by the total number of infants hospitalized during the period of early-onset
and late-onset sepsis, respectively. We compared across groups using chi-square test of
association and Wilcoxon rank sum test for categorical and continuous variables,
respectively.
We used univariable logistic regression to evaluate the association between the 4 separate
outcomes: GBS early- and late-onset SBI and E. coli early- and late-onset SBI and the
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following predictor variables: gestational age, sex, race, inborn status, 5-minute Apgar,
ventilator support on the first postnatal day, prenatal steroid exposure, prenatal antibiotic
exposure, mode of delivery, and admission during 2 time periods of 1997–2001 and 2002–
2010. These 2 time periods were chosen to indicate the periods prior to and after the
institution of universal recommendations for IAP. All variables significant at the univariable
level were included in the final multivariable model, which included the following
predictors: gestational age, sex, race, inborn status, 5-minute Apgar, ventilator support on
the first postnatal day, prenatal steroid exposure, prenatal antibiotic exposure, and mode of
delivery. Birth weight was removed from the final model due to collinearity with gestational
age. A P-value <0.05 was considered statistically significant, and all analyses were
performed using Stata 12 (College Station, TX). The Duke University Institutional Review
Board and the Western Institutional Review Board granted permission to conduct this
analysis on the de-identified data set.
RESULTS
Overall
We identified 716,407 infants during the study period; 2520 (0.4%) infants had 2551
episodes of GBS SBI, 2476 (0.3%) infants had 2532 episodes of E. coli SBI, and 18 infants
(0.003%) were infected with both. Compared to infants with E. coli SBI, infants with GBS
SBI were more mature (median gestational age 38 weeks [25th, 75th percentile: 30, 39] vs.
30 weeks [26, 35], P<0.001), larger (2927 g [1405, 3452] vs. 1356 g [845, 2370], P<0.001),
and less often exposed to maternal antibiotics (25% vs. 55%, P<0.001).
Early-onset SBI
Of the 2551 GBS infections, 1869 (73%) were early-onset SBI. Of the 2532 E. coli
infections, 971(38%) were early-onset SBI. When compared to infants with E. coli early-
onset SBI, infants with GBS early-onset SBI had a greater gestational age (38 weeks [36,
40] vs. 32 weeks [28, 38], P<0.001), higher birth weights (3196 g [2670, 3570] vs. 1855 g
[1110, 2950], P<0.001), and fewer were exposed to antenatal antibiotics (19% vs. 59%,
P<0.001) (Table 1). Of the 2839 early-onset SBI, 2257 (80%) infections occurred from
2002–2010 (Table 2).
Nearly all episodes of GBS and E. coli early-onset SBI were bloodstream infections: 1839
(98%) of GBS and 956 (98%) of E.coli SBIs (Table 3). SBI co-infections were uncommon
in GBS early-onset SBI: 4 (<1%) episodes were bloodstream infections and urinary tract
infections; 15 (<1%) were bloodstream infections and meningitis. Few infants with E. coli
early-onset SBI had meningitis alone (4, <1%). Co-infections were uncommon in E. coli
early-onset SBI: 2 episodes (<1%) with bloodstream infections and meningitis and no
episodes with bloodstream infections and urinary tract infections.
The incidence of GBS early-onset SBI from 1997–2001 to 2002–2010 decreased from 3.5 to
2.6 per 1000 admissions (Figure 1). On multivariable regression, the odds of developing
GBS early-onset SBI were lower (odds ratio [OR]=0.69; 95% confidence interval [CI]: 0.59,
0.80]; P<0.001) in the later time period.
The incidence of E. coli early-onset SBI was 1.4 per 1000 admissions during both time
periods (Figure 1). On multivariable regression, the odds of developing E. coli early-onset
SBI were not significantly different between the 2 time periods (OR=0.95; 95% CI 0.78,
1.16; P=0.63).
Mortality among infants with E. coli early-onset SBI was higher than in those with GBS
early-onset SBI (10% vs. 4%, P<0.001) (Table 4). Among infants who died with GBS early-
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onset SBI, 53% (38/72) died within 7 days of a positive culture. Among infants who died
with E. coli early-onset SBI, 44% (38/86) died within 7 days of a positive culture.
Late-onset SBI
Of the 2551 GBS SBIs, 682 (27%) were late-onset SBI. Of the 2532 E. coli SBIs, 1561
(62%) were late-onset SBI. There was no significant difference between the infants with
GBS late-onset SBI compared to infants with E. coli late-onset SBI in gestational age (28
weeks [26, 31] vs. 28 weeks [25, 33]; P=0.63), birth weight (1090 g [816, 1533] vs. 1124 g
[770, 1905]; P=0.17), exposure to antenatal steroids (63% vs. 61%, P=0.52), or the need for
mechanical ventilation on the first postnatal day (66% vs. 65%, P=0.55) (Table 1). Of the
2185 late-onset SBI, 1858 (85%) infections occurred from 2002–2010 (Table 2).
Nearly all episodes of GBS late-onset SBI were bloodstream infections (626 [92%]; Table
3). Co-infections in GBS late-onset SBIs were rare: 1 (<1%) with bloodstream and urinary
tract infections and 31 (5%) with bloodstream and CSF infections. Similarly, nearly all
episodes of E. coli late-onset SBI were bloodstream infections (1344 [86%]; Table 3).
However, E. coli late-onset SBI included 174 (11%) urinary tract infections; 6 (<1%) had
both a bloodstream infection and a urinary tract infection. A small number of infants had
meningitis (32 [2%]).
The incidence of GBS late-onset SBI from1997–2001 to 2002–2010 increased from 0.8 to
1.1 per 1000 admissions (Figure 2). On multivariable regression, the odds of developing
GBS late-onset SBI were higher (OR=1.67 [95% CI 1.23, 2.25], P=0.001) in the later time
period.
The incidence of E. coli late-onset SBI from 1997–2001 to 2002–2010 increased from 2.2 to
2.5 per 1000 admissions (Figure 2). On multivariable regression, the odds of developing E.
coli late-onset SBI were not significantly different between the 2 time periods (OR=1.17
[95% CI 0.99, 1.39], P=0.06).
Mortality was higher in infants infected with E. coli late-onset SBI compared with GBS late-
onset SBI (14% vs. 7%, P<0.001; Table 4). Among infants who died with GBS late-onset
SBI, 44% (19/43) died within 7 days of a positive culture. Among infants who died with E.
coli late-onset SBI, 10% (19/190) died within 7 days of a positive culture.
Infants in the latter time period were smaller with lower gestational ages: among all infants
who died from 1997–2001, mean gestational age was 27.6 weeks (24, 36) and mean birth
weight 1261 g (580, 3218) versus those who died from 2002–2010, whose mean gestational
age was 26.7 weeks (23, 35) and mean birth weight 1011 g (520, 2610).
DISCUSSION
In our cohort of admissions to a large number of NICUs, the incidence of GBS early-onset
SBI decreased after the institution of universal IAP, and no change was observed in the
incidence of E. coli early-onset SBI. We observed an increase in the incidence of GBS late-
onset SBI from 1997–2001 to 2002–2010. Mortality in infants infected by late-onset SBI
increased over time, and we speculate that changes in neonatal practice, including improved
survival of VLBW infants with lower gestational ages, have contributed to increased
susceptibility to infection and a resulting increase in mortality.
Our data are consistent with previous reports of a declining incidence of GBS early-onset
SBI. The majority of previous studies are limited to infections in the bloodstream12,14 or
bloodstream and CSF15; however, our study included urinary tract infections. In a report of
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bloodstream infections among VLBW infants, the National Institute of Child Health and
Human Development Neonatal Research Network found a lower incidence (1.7 per 1000
live-born VLBW infants) of early-onset GBS bloodstream infections in infants born between
1998 and 2000 when compared to the incidence (5.9 per 1000 live-born VLBW infants) in
infants born from 1991–1993.12 The Centers for Disease Control and Prevention reported an
annual incidence of GBS early-onset SBI 33% lower from 2003–2005 compared to 2000–
2001 among all infants.15 Our data, including full-term and premature infants, demonstrate a
similar decline in incidence in GBS early-onset SBIs.
Previous studies on the changes in the incidence of E. coli early-onset SBI are less clear.
Some studies report stable incidence of E. coli early-onset SBI,16–18 while others have
observed an increased incidence of E. coli early-onset SBI, particularly among VLBW
infants.1,12 A review of infection data of VLBW infants in the Neonatal Research Network
demonstrated an increase in the incidence of E. coli bloodstream infections from 3.2 per
1000 live births from 1991–1993 to 6.8 per 1000 live births from 1998–2000.1 In contrast, a
retrospective review of blood cultures obtained from 647 infected infants in a single-site
NICU population showed stable incidence of E. coli early-onset SBI.4 In our population of
term and premature infants, we observed a stable incidence of E. coli early-onset SBI over
time (1.4 per 1000 admissions).
We observed an increased incidence of GBS late-onset SBIs after 2002, when the
recommendations for universal IAP were released. Previously published data conflict in
regards to changes in the incidence of late-onset SBI; some studies report an unchanged
incidence of late-onset bloodstream infections,17,19 while others have reported an increasing
incidence.4,13,20,21 E. coli late-onset SBI increased among term and premature infants after a
single center adopted universal IAP recommendations.13
Our study included urine cultures obtained by catheterization or suprapubic tap, an
important source of neonatal infectious morbidity and mortality. Urinary tract infections are
common, occurring in 8% in VLBW infants, and repeated infections are associated with
renal scarring that can lead to end-stage renal SBI.22,23 Hematogenous seeding of the
urinary tract may be responsible for the increasing incidence of late-onset urinary tract
infections in the immune-compromised infant, with increased susceptibility in very low birth
weight infants.23
One potential cause of the observed increased incidence of late-onset SBI after universal
IAP is that IAP has “shifted” the SBI onset of GBS and E. coli into the period beyond the
first postnatal days.24 In an epidemiologic study of full-term, previously healthy infants, IAP
was found to be associated with late-onset SBI.25 Microbiologic pressure from the
increasing use of IAP might be another explanation for our findings, leading to a change in
pathogenic organisms. Previous studies have reported an increase in the incidence of gram-
negative rod infections as the use of IAP has increased.12,26 Increased use of IAP may
promote the emergence of antibiotic-resistant organisms that become clinically evident after
the first few postnatal days. Antibiotic use has been associated with changes in pathogenic
organism patterns in neonatal populations. For example, increased fungal infections have
been reported in NICUs that widely use cephalosporins.27 Our study population included
more low birth weight infants over time, and this variation might also account for a portion
of the increased incidence of late-onset SBI.28
This study is among the largest reported evaluations of early- and late-onset SBI caused by
GBS and E. coli. The strengths of this report include the large sample size, a diverse patient
population drawn from academic and community institutions, inclusion of maternal and
infant risk factors for sepsis, and the use of data prior to and after universal IAP
Bauserman et al. Page 5













recommendations. The study is limited to infants admitted to NICUs and may under-
represent the total burden of late-onset SBI by excluding infants presenting to pediatric
intensive care units, emergency departments, and inpatient pediatric units or over-represent
hospital-acquired nosocomial infections. Urine and CSF cultures were obtained at the
discretion of the clinician, which might have limited our ability to determine true co-
infection rates. The study is also limited by the lack of documentation of clinical signs of
sepsis, lack of information about which antibiotic was administered as IAP, and resistance
patterns of the bacterial isolates.
In conclusion, we found that the incidence of GBS late-onset SBI increased in the era
following IAP recommendations. This may represent an epidemiological shift in pathogenic
organisms, or it could represent increased vulnerability to infections in very premature
infants. Further examination is needed to determine whether IAP has resulted in an overall
decrease in SBI burden and mortality or merely shifted the burden to a later time point or to
a different site of infection. Future research should examine a population-based cohort that
includes early- and late-onset SBI, bloodstream infections, urinary tract infections, and
meningitis. Trends in mortality from sepsis, particularly among low birth weight infants,
should also continue to be monitored at the level of the population as pathogenic organisms
shift.
Acknowledgments
Sources of funding: Dr. Laughon receives support from the U.S. government for his work in pediatric and neonatal
clinical pharmacology (Government Contract HHSN267200700051C [PI: Benjamin] under the Best
Pharmaceuticals for Children Act and 1K23HL092225-01). Dr. Benjamin receives support from the U.S.
government for his work in pediatric and neonatal clinical pharmacology (1R01HD057956-02, 1R01FD003519-01,
1U10-HD45962-06, 1K24HD058735-01, and Government Contract HHSN267200700051C under the Best
Pharmaceuticals for Children Act), the non-profit organization Thrasher Research Foundation for his work in
neonatal candidiasis, and from industry for neonatal and pediatric drug development (http://www.dcri.duke.edu/
research/coi.jsp). Dr. Smith receives support from the U.S. government for his work in pediatric and neonatal
pharmacology (NICHD 1K23HD060040-01) and epidemiology (DHHS-1R18AE000028-01). Dr. Cohen-
Wolkowiez receives support from the U.S. government for his work in pediatric and neonatal pharmacology
(NICHD 1K23HD064814-01) and from industry for neonatal and pediatric drug development (http://
www.dcri.duke.edu/research/coi.jsp).
References
1. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research
Network. Semin Perinatol. 2003; 27:293–301. [PubMed: 14510320]
2. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among
extremely low-birth-weight infants with neonatal infection. JAMA. 2004; 292:2357–2365.
[PubMed: 15547163]
3. Schrag SJ, Stoll BJ. Early-onset neonatal sepsis in the era of widespread intrapartum
chemoprophylaxis. Pediatr Infect Dis J. 2006; 25:939–940. [PubMed: 17006292]
4. Bizzarro MJ, Raskind C, Baltimore RS, Gallagher PG. Seventy-five years of neonatal sepsis at Yale:
1928–2003. Pediatrics. 2005; 116:595–602. [PubMed: 16140698]
5. Stoll BJ, Hansen NI, Sanchez PJ, et al. Early onset neonatal sepsis: the burden of group B
streptococcal and E. coli disease continues. Pediatrics. 2011; 127:817–826. [PubMed: 21518717]
6. Baker CJ, Byington CL, Polin RA. Policy statement: recommendations for the prevention of
perinatal group B streptococcal (GBS) disease. Pediatrics. 2011; 128:611–616. [PubMed:
21807694]
7. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the
United States, 2005–2008. Pediatr Infect Dis J. 2011; 30:937–941. [PubMed: 21654548]
8. Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group
B Streptococcus. N Engl J Med. 2009; 360:2626–2636. [PubMed: 19535801]
Bauserman et al. Page 6













9. Goins WP, Talbot TR, Schaffner W, et al. Adherence to perinatal group B streptococcal prevention
guidelines. Obstet Gynecol. 2010; 115:1217–1224. [PubMed: 20502293]
10. Early-onset and late-onset neonatal group B streptococcal disease—United States, 1996–2004.
MMWR Morb Mortal Wkly Rep. 2005; 54:1205–1208. [PubMed: 16319814]
11. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease—revised
guidelines from CDC, 2010. MMWR Recomm Rep. 2010; 59:1–36. [PubMed: 21088663]
12. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-
low-birth-weight infants. N Engl J Med. 2002; 347:240–247. [PubMed: 12140299]
13. Lukacs SL, Schoendorf KC, Schuchat A. Trends in sepsis-related neonatal mortality in the United
States, 1985–1998. Pediatr Infect Dis J. 2004; 23:599–603. [PubMed: 15247595]
14. Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of
maternal screening. Pediatrics. 2005; 115:1240–1246. [PubMed: 15867030]
15. Perinatal group B streptococcal disease after universal screening recommendations—United States,
2003–2005. MMWR Morb Mortal Wkly Rep. 2007; 56:701–705. [PubMed: 17637595]
16. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for
prevention of group B streptococcal disease on the incidence and ecology of early-onset neonatal
sepsis. Lancet Infect Dis. 2003; 3:201–213. [PubMed: 12679263]
17. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum
antibiotic prophylaxis. N Engl J Med. 2000; 342:15–20. [PubMed: 10620644]
18. Alarcon A, Pena P, Salas S, Sancha M, Omenaca F. Neonatal early onset Escherichia coli sepsis:
trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial
prophylaxis. Pediatr Infect Dis J. 2004; 23:295–299. [PubMed: 15071281]
19. Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease
in the United States, 1999–2005. JAMA. 2008; 299:2056–2065. [PubMed: 18460666]
20. Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. Changing patterns in neonatal Escherichia
coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics.
2008; 121:689–696. [PubMed: 18381532]
21. Ecker KL, Donohue PK, Kim KS, Shepard JA, Aucott SW. The impact of group B Streptococcus
prophylaxis on late-onset neonatal infections. J Perinatol. 2012 Jun 14. [Epub ahead of print].
10.1038/jp.2012.76
22. Nowell L, Moran C, Smith PB, et al. Prevalence of renal anomalies after urinary tract infections in
hospitalized infants less than 2 months of age. J Perinatol. 2010; 30:281–285. [PubMed:
19812586]
23. Bauer S, Eliakim A, Pomeranz A, et al. Urinary tract infection in very low birth weight preterm
infants. Pediatr Infect Dis J. 2003; 22:426–430. [PubMed: 12792383]
24. Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset
neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis
J. 2008; 27:1057–1064. [PubMed: 18989238]
25. Glasgow TS, Young PC, Wallin J, et al. Association of intrapartum antibiotic exposure and late-
onset serious bacterial infections in infants. Pediatrics. 2005; 116:696–702. [PubMed: 16140710]
26. Stoll BJ, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with early onset
neonatal sepsis: the predominance of gram-negative infections continues in the National Institute
of Child Health and Human Development Neonatal Research Network, 2002–2003. Pediatr Infect
Dis J. 2005; 24:635–639. [PubMed: 15999007]
27. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr. The association of
third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants.
Pediatrics. 2006; 118:717–722. [PubMed: 16882828]
28. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged
younger than 3 months: systematic review and meta-analysis. Lancet. 2012; 379:547–556.
[PubMed: 22226047]
Bauserman et al. Page 7














Incidence of early-onset serious bacterial infections over time. E. coli indicates Escherichia
coli, EOS, early-onset sepsis, GBS, group B Streptococcus.
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Incidence of late-onset serious bacterial infections over time. E. coli indicates Escherichia
coli, GBS, group B Streptococcus, LOS, late-onset sepsis.
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Table 1
Demographics of study patients at enrollment (N=248)
No. %
Sex
 Male 135 54.4





 Non-Hispanic White 147 59.3
 African American 48 19.4
 Asian 2 0.8
 Hispanic 12 4.8
 Other 39 15.7
Family History of OM
 Maternal 34 13.8
 Paternal 15 6.1
 Sibling 24 9.7
 >1 Family Member 20 8.1
 None/Missing 155 62.3
Daycareα
 Home 49 60.5
 Center 29 35.8
 Combination (Home and Center) 3 3.7
Breast-feedingα
 <6 months 28 11.3
 ≥6 months 33 13.3
 Formula 86 34.7
 Combination (Formula and breast milk) 81 31.6
Antibiotic Exposure (Number of visits)
 Use in 0–30 days prior to visit 106 8.6
 No antibiotic Use or 30+ days prior to visit 1133 91.4
α
Variables collected at enrollment; daycare had 167 missing values, breast-feeding had 20 missing values
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Table 2
Predicted outcome of colonization with AHS in young children (N=1146 visits)
Parameters OR (95% CI) P-value
Colonization by S. pneumoniae
 No (reference) 1.0
 Yes 0.172 (0.125–0.238) <0.001
Colonization by H. influenzae
 No (reference) 1.0
 Yes 1.254 (0.803–1.957) 0.320
Colonization by M. catarrhalis
 No (reference) 1.0
 Yes 1.271 (0.963–1.676) 0.090
Visit type
 β AOM 1.0
 Non-AOM 2.135(1.355–3.365) 0.001
 Follow Up 2.122(0.966–4.665) 0.061
Presence of URI symptoms
 No (reference) 1.0
 Yes 1.139 (0.782–1.660) 0.498
Sex
 Male 1.0
 Female 1.161 (0.868–1.554) 0.313
Exposure to tobacco smoke
 No (reference) 1.0
 Yes 0.820 (0.533–1.263) 0.369
Age (months) 1.010 (0.990–1.032) 0.316
Breastfed
 Formula(reference) 1.0
 Less than 6 months 1.787 (0.992–3.219) 0.053
 More than 6 months 1.164 (0.761–1.780) 0.483
 Combination (Formula + Breastfeeding) 0.883 (0.631–1.237) 0.471
Daycare
 Home 1.0
 Center 0.817 (0.477–1.401) 0.463
 Both 0.362 (0.088–1.486) 0.158
Antibiotic Exposure in the last 30 days
 No (reference) 1.0
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Parameters OR (95% CI) P-value
 Yes 0.969 (0.533–1.761) 0.920
Family History
 No (reference) 1.0
 Yes 1.150 (0.862–1.535) 0.342
Associations with a significant p-value (p ≤ 0.05) are indicated in bold lettering
β
When the model included Non-AOM as the reference for visit type, the OR and p-value were; 0.488, p=0.002
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TABLE 3
Site of Infection for Infants with Early-onset and Late-onset Serious Bacterial Infection
Early-onset SBI, n (%) Late-onset SBI, n (%)
GBS E. coli GBS E. coli
n 1869 971 663 1522
Blood 1839 (98) 956 (98) 626 (92) 1344 (86)
Urine 5 (<1) 9 (<1) 13 (2) 174 (11)
CSF 6 (<1) 4 (<1) 11 (2) 32 (2)
Blood & urine 4 (<1) 0 (0) 1 (<1) 6 (<1)
Blood & CSF 15 (<1) 2 (<1) 31 (5) 5 (<1)
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TABLE 4
Mortality of Infants with Early-onset and Late-onset Serious Bacterial Infection Before and After Universal
Intrapartum Antibiotic Prophylaxis Recommendations
Early-onset SBI, n (%) Late-onset SBI, n (%)
GBS E. coli GBS E. coli
Mortality 72/1751 (4) 86/882 (10) 41/584 (7) 184/1307 (14)
 1997–2001 17/381 (4) 14/156 (9) 3/71 (4) 16/212 (8)
 2002–2010 55/1370 (4) 72/726 (10) 38/513 (7) 168/1095 (15)
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